Clinical Trials Browser

Phase 2 × OTHER × Non-squamous Non-small-cell Lung Cancer × Clear all

NCT05258279 2024-08-28

Lenvatinib in Combination With Carboplatin Pemetrexed and Pembrolizumab for NSCLC With EGFR Mutations

Phase 2 Active not recruiting

Non-squamous Non-small-cell Lung Cancer